Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in Chinese participants with overweight or obesity
NCT05996848Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cagrilintide in obesity, sponsored by Novo Nordisk. Started Aug 2023; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05996848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05996848.